Mucosal immunization with a replication-deficient adenovirus vector expressing murine cytomegalovirus glycoprotein B induces mucosal and systemic immunity.

Abstract:

:The murine cytomegalovirus (MCMV) glycoprotein B (gB) gene was expressed in an adenovirus replication-deficient vector. This virus, designated Ad-gB, was used to immunize BALB/c and B6 mice by the intranasal (i.n.) route to induce an immune response. Following primary immunization, antibody was detected in serum of 100% of vaccinees, as well as the bronchoalveolar lavage, fecal suspensions and vaginal washings. The viral titer of lung and salivary gland of vaccinees 10 days after intranasal challenge with MCMV at 10(5) or 10(3)plaque forming units (PFU) were significantly reduced compared to controls. Re-exposure of vaccinees to Ad-gB 30 days after primary immunization induced a remarkable boost of serum and mucosal antibody responses and further reduction of MCMV titers in the lung and salivary glands. The ability to induce both a systemic and mucosal immune response to a specific gene product may be important in reducing horizontal transmission of CMV infections across mucosal surfaces and in altering host immunity to CMV.

journal_name

Vaccine

journal_title

Vaccine

authors

Shanley JD,Wu CA

doi

10.1016/s0264-410x(03)00037-9

subject

Has Abstract

pub_date

2003-06-02 00:00:00

pages

2632-42

issue

19-20

eissn

0264-410X

issn

1873-2518

pii

S0264410X03000379

journal_volume

21

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice.

    abstract::The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranasal Protollin-formul...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.06.017

    authors: Hu MC,Jones T,Kenney RT,Barnard DL,Burt DS,Lowell GH

    更新日期:2007-08-21 00:00:00

  • Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine.

    abstract::TA-CIN is a vaccine that comprises the human papillomavirus (HPV) type 16 L2, E6 and E7 as a single fusion protein. In a mouse model, TA-CIN effectively prevented outgrowth of HPV16-positive tumour cells. To assess the safety and immunogenicity of TA-CIN, a dose escalating (26, 128, 533 micro g), double blind and plac...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0264-410x(02)00350-x

    authors: de Jong A,O'Neill T,Khan AY,Kwappenberg KM,Chisholm SE,Whittle NR,Dobson JA,Jack LC,St Clair Roberts JA,Offringa R,van der Burg SH,Hickling JK

    更新日期:2002-10-04 00:00:00

  • ArtinM, a D-mannose-binding lectin from Artocarpus integrifolia, plays a potent adjuvant and immunostimulatory role in immunization against Neospora caninum.

    abstract::ArtinM and Jacalin (JAC) are lectins from the jackfruit (Artocarpus integrifolia) that have important role in modulation of immune responses to pathogens. Neospora caninum is an Apicomplexa parasite that causes neuromuscular disease in dogs and reproductive disorders in cattle, with economic impact on the livestock in...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.09.136

    authors: Cardoso MR,Mota CM,Ribeiro DP,Santiago FM,Carvalho JV,Araujo EC,Silva NM,Mineo TW,Roque-Barreira MC,Mineo JR,Silva DA

    更新日期:2011-11-15 00:00:00

  • Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries.

    abstract::The costs of developing and producing new-generation vaccines have increased compared to many of the older, "traditional" vaccines because of new technologies and regulatory requirements. While the public sector often supports basic research costs, private manufacturers are usually responsible for the investments in p...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2006.05.042

    authors: Batson A,Meheus F,Brooke S

    更新日期:2006-08-31 00:00:00

  • Comparative immunogenicity in children of mammalian cell-derived recombinant hepatitis B vaccine and plasma-derived hepatitis B vaccine.

    abstract::Three doses of hepatitis B vaccine were given at 2, 4 and 9 months of age to 220 Senegalese infants living in the Dakar area of Senegal. Half of the infants received 5 micrograms plasma-derived hepatitis B vaccine (Hevac B) and the remainder 20 micrograms mammalian cell-derived recombinant hepatitis B vaccine (GenHeva...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(92)90067-t

    authors: Coursaget P,Bringer L,Sarr G,Bourdil C,Fritzell B,Blondeau C,Yvonnet B,Chiron JP,Jeannée E,Guindo S

    更新日期:1992-01-01 00:00:00

  • Distribution of adsorbed antigen in mono-valent and combination vaccines.

    abstract::The distribution of alpha-casein, bovine serum albumin (BSA), myoglobin and recombinant protective antigen (rPA) in mono-valent and combination vaccines containing aluminum hydroxide adjuvant was studied by fluorescence microscopy and flow cytometry. Green and red fluorescent probes were conjugated to the antigens. Ad...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2003.10.040

    authors: Morefield GL,HogenEsch H,Robinson JP,Hem SL

    更新日期:2004-05-07 00:00:00

  • Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials.

    abstract::The use of pneumococcal polysaccharide vaccine (PPV) is low in some countries, maybe because of doubts regarding its efficacy. This meta-analysis aims at combining evidence from randomized trials of PPV assessing its efficacy in preventing Streptococcus pneumoniae related diseases in immunocompetent adults. In the fou...

    journal_title:Vaccine

    pub_type: 杂志文章,meta分析

    doi:10.1016/s0264-410x(01)00217-1

    authors: Cornu C,Yzèbe D,Léophonte P,Gaillat J,Boissel JP,Cucherat M

    更新日期:2001-09-14 00:00:00

  • Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

    abstract::M2 is the third integral membrane protein of influenza A. M2e, the extracellular, 23 amino acid residues of M2, has been remarkably conserved in all human influenza A strains. This prompted us to evaluate the use of M2e as a potential broad-spectrum immunogen in a mouse model for influenza infection. Genetic fusion of...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.05.082

    authors: De Filette M,Fiers W,Martens W,Birkett A,Ramne A,Löwenadler B,Lycke N,Jou WM,Saelens X

    更新日期:2006-11-10 00:00:00

  • Post-marketing safety surveillance for inactivated and live-attenuated Japanese encephalitis vaccines in China, 2008-2013.

    abstract:INTRODUCTION:Two types of Japanese encephalitis (JE) vaccines, inactivated JE vaccine (JE-I) and live-attenuated JE vaccine (JE-L), are available and used in China. In particular, one JE-L, produced by a domestic manufacturer in China, was prequalified by WHO in 2013. We assessed the safety of JE vaccines in China duri...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.05.021

    authors: Wu W,Liu D,Li K,Nuorti JP,Nohynek HM,Xu D,Ye J,Zheng J,Wang H

    更新日期:2017-06-22 00:00:00

  • Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity.

    abstract::We evaluated invasive pneumococcal disease (IPD), antimicrobial resistance and nasopharyngeal colonization before and after introduction of pneumococcal conjugate vaccine (PCV7) in Alaska Natives (AN), a population with high IPD rates. We obtained IPD rates from population-based surveillance. Colonization was determin...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.08.100

    authors: Hennessy TW,Singleton RJ,Bulkow LR,Bruden DL,Hurlburt DA,Parks D,Moore M,Parkinson AJ,Schuchat A,Butler JC

    更新日期:2005-12-01 00:00:00

  • The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007.

    abstract::Active surveillance was conducted by the 12 centers of the Canadian Immunization Monitoring Program, Active from 2000-2007 in children 16 years of age and younger to determine the influence of 7-valent pneumococcal conjugate immunization programs on the prevalence, serotype and antibiotic resistance patterns of invasi...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.vaccine.2009.12.026

    authors: Bettinger JA,Scheifele DW,Kellner JD,Halperin SA,Vaudry W,Law B,Tyrrell G,Canadian Immunization Monitoring Program, Active (IMPACT).

    更新日期:2010-02-25 00:00:00

  • Oral cholera vaccines containing B-subunit-killed whole cells and killed whole cells only. II. Field evaluation of cross-protection against other members of the Vibrionaceae family.

    abstract::Because of demonstrable cross-reactivity of cellular antigens contained in B subunit-killed whole-cell (BS-WC) and killed whole-cell-only (WC) oral cholera vaccines with antigens of various non-cholera species of the family Vibrionaceae (NCV), the protection conferred by the vaccines against diarrhoea associated with ...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0264-410x(89)90048-0

    authors: Clemens JD,Harris JR,Kay BA,Chakraborty J,Sack DA,Ansaruzzaman M,Rahman R,Stanton BF,Khan MU,Khan MR

    更新日期:1989-04-01 00:00:00

  • Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B- and T-cell epitopes of the Plasmodium falciparum CS protein: possible vaccine application.

    abstract::Multiple-antigen peptides (MAPs), containing B- and T-cell epitopes of the Plasmodium falciparum circumsporozoite (CS) protein, have been designed to overcome the limitations of first-generation peptide vaccines caused by low epitope density, carrier toxicity and the lack of parasite-derived T-cell epitopes. The immun...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(94)90337-9

    authors: de Oliveira GA,Clavijo P,Nussenzweig RS,Nardin EH

    更新日期:1994-08-01 00:00:00

  • Would an in vitro ELISA test be a suitable alternative potency method to the in vivo immunogenicity assay commonly used in the context of international Hepatitis A vaccines batch release?

    abstract::Since many years Afssaps applies the 3R's strategy (replacement, reduction and refinement) for the use of laboratory animal testing in the framework of vaccine batch release. In this context, for Hepatitis A vaccines, a study was carried out to assess the feasibility of replacing the in vivo "Gold Standard" potency as...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.12.006

    authors: Poirier B,Variot P,Delourme P,Maurin J,Morgeaux S

    更新日期:2010-02-17 00:00:00

  • Expression of HIV-1 envelope gene by recombinant avipox viruses.

    abstract::Recombinant canarypox (CP) and fowlpox (FP) viruses that contained two forms of the HIV-1 (SF2 strain) env gene were engineered and their expression analysed in chick, simian and human cells. These vectors can efficiently replicate in avian but not in mammalian cells, in which infection is abortive. The two forms, con...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(94)90180-5

    authors: Radaelli A,De Giuli Morghen C

    更新日期:1994-09-01 00:00:00

  • Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge.

    abstract::Thirty-two rhesus monkeys were used to evaluate the dose response of a recombinant HEV vaccine, and the efficacy of the vaccine based on the ORF2 protein of the Pakistani strain for pre- and post-exposure vaccination against intravenous challenge with homologous or heterologous virus was examined. Post-exposure vaccin...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(97)00145-x

    authors: Tsarev SA,Tsareva TS,Emerson SU,Govindarajan S,Shapiro M,Gerin JL,Purcell RH

    更新日期:1997-12-01 00:00:00

  • Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2-17-year-old children with asplenia or splenic dysfunction: A phase 3 study.

    abstract:BACKGROUND:Immunization with pneumococcal vaccines is an important prophylactic strategy for children with asplenia or splenic dysfunction, who are at high risk of bacterial infections (including S. pneumoniae). This study aimed to assess immunogenicity and safety of pneumococcal non-typeable Haemophilus influenzae pro...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.vaccine.2017.08.039

    authors: Szenborn L,Osipova IV,Czajka H,Kharit SM,Jackowska T,François N,Habib MA,Borys D

    更新日期:2017-09-25 00:00:00

  • Vero-cell rabies vaccine produced using serum-free medium.

    abstract::A new rabies vaccine was developed from Vero cells adhered to microcarriers, cultivated in a bioreactor in serum-free medium and infected with the PV/VERO-Paris rabies virus strain. The viral suspensions were concentrated by tangential filtration, purified by chromatography and inactivated with beta-propiolactone. In ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.06.014

    authors: Frazatti-Gallina NM,Mourão-Fuches RM,Paoli RL,Silva ML,Miyaki C,Valentini EJ,Raw I,Higashi HG

    更新日期:2004-12-09 00:00:00

  • T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague.

    abstract::Plague, which is initiated by Yersinia pestis infection, is a fatal disease that progresses rapidly and leads to high mortality rates if not treated. Antibiotics are an effective plague therapy, but antibiotic-resistant Y. pestis strains have been reported and therefore alternative countermeasures are needed. In the p...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.07.059

    authors: Levy Y,Flashner Y,Tidhar A,Zauberman A,Aftalion M,Lazar S,Gur D,Shafferman A,Mamroud E

    更新日期:2011-09-16 00:00:00

  • Prevention of perinatal hepatitis B virus transmission in the Netherlands, 2003-2007: children of Chinese mothers are at increased risk of breakthrough infection.

    abstract:BACKGROUND:In the Netherlands, different hepatitis B vaccination schedules have been used for children born to HBV-infected mothers. All schedules included a birth dose of hepatitis B immunoglobuline (HBIg). We assessed determinants of perinatal HBV transmission and determinants of anti-HBs titers in infants born to HB...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.12.071

    authors: Hahné S,van den Hoek A,Baayen D,van der Sande M,de Melker H,Boot H

    更新日期:2012-02-21 00:00:00

  • Epidemiological patterns of hepatitis A in different parts of the world.

    abstract::Serological surveys in many communities show a high prevalence of antibodies to hepatitis A virus (HAV) in people over the age of 50 years. However, few of that age can recall a previous episode of hepatitis, indicating that subclinical infections are common. The outcome of infection with HAV depends on the age at whi...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/0264-410x(92)90544-t

    authors: Gust ID

    更新日期:1992-01-01 00:00:00

  • New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation.

    abstract::Few suspension cells can be used for vaccine manufacturing today as they either do not meet requirements from health regulatory authorities or do not produce high virus titres. Two new avian designer cell lines (AGE1.CR and AGE1.CR.pIX) that have been adapted to grow in suspension in serum-free medium were evaluated f...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.05.083

    authors: Lohr V,Rath A,Genzel Y,Jordan I,Sandig V,Reichl U

    更新日期:2009-08-06 00:00:00

  • Safe vaccination of children with a virosomal adjuvanted influenza vaccine.

    abstract::A post-marketing study was conducted in 26 paediatric practices in Germany to collect safety information on the virosomal adjuvanted influenza vaccine Inflexal V (in Germany marketed as Infectovac Flu). Children aged 6 months to 6 years received one or two doses. Adverse events were documented by parents/legal guardia...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.12.008

    authors: Künzi V,Dornseiff M,Horwath J,Hartmann K

    更新日期:2009-02-18 00:00:00

  • The feasibility of identifying children with primary immunodeficiency disorders: preparation for the polio post-eradication era in Bangladesh.

    abstract:BACKGROUND:Persons with primary immunodeficiency disorders (PIDD) who receive oral poliovirus vaccine (OPV) or are household contacts of OPV recipients are at risk of excreting immunodeficiency-associated vaccine-derived polioviruses (iVDPVs). iVDPVs can be transmitted and cause paralytic polio. The objective of this s...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.06.017

    authors: Sazzad HM,Rainey JJ,Mach O,Sutter R,Diordista S,Kawser CA,Mobarak R,Alam D,Chowdhury MA,Hossain MJ,Hasan AS,Luby SP

    更新日期:2012-08-03 00:00:00

  • The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs.

    abstract::Herpes simplex virus (HSV) infections are common but there is no vaccine available. We evaluated cationic liposome-DNA complexes (CLDC) as an adjuvant for an HSV gD2 vaccine and compared it to an MPL/Alum adjuvant in a guinea pig model of genital herpes. The addition of CLDC to the gD2 vaccine significantly decreased ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.10.025

    authors: Bernstein DI,Farley N,Bravo FJ,Earwood J,McNeal M,Fairman J,Cardin R

    更新日期:2010-05-07 00:00:00

  • Re-emergence of the type 1 pilus among Streptococcus pneumoniae isolates in Massachusetts, USA.

    abstract::Pneumococcal type 1 pilus proteins have been proposed as potential vaccine candidates. Following conjugate pneumococcal vaccination, the prevalence of the pneumococcal type 1 pilus declined dramatically, a decline associated with the elimination of vaccine-type (VT) strains. Here we show that between 2004 and 2007, th...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.04.042

    authors: Regev-Yochay G,Hanage WP,Trzcinski K,Rifas-Shiman SL,Lee G,Bessolo A,Huang SS,Pelton SI,McAdam AJ,Finkelstein JA,Lipsitch M,Malley R

    更新日期:2010-07-05 00:00:00

  • Impact and cost effectiveness of pneumococcal conjugate vaccine in India.

    abstract:BACKGROUND:World Health Organization has recommended the introduction of pneumococcal conjugate vaccine (PCV) in the childhood immunisation programme of all the countries in the world. In lieu of its introduction in India, there is a need to generate evidence on cost-effectiveness of this vaccine. The current study loo...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.12.004

    authors: Krishnamoorthy Y,Eliyas SK,Nair NP,Sakthivel M,Sarveswaran G,Chinnakali P

    更新日期:2019-01-21 00:00:00

  • Improved safety of a replication-competent poxvirus-based HIV vaccine with the introduction of the HSV-TK/GCV suicide gene system.

    abstract:INTRODUCTION:Replication-competent vaccinia viruses (VACVs) show prolonged antigen expression time and greater stimulation of immune responses than their replication-incompetent counterparts. However, there is the potential risk of serious post-vaccination complications, especially for children and immunocompromised in...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.05.012

    authors: Zhang Q,Liu Z,Hou J,Wang S,Liu C,Wei M,Liu Y,Shao Y

    更新日期:2016-06-24 00:00:00

  • Infant vaccination timing: Beyond traditional coverage metrics for maximizing impact of vaccine programs, an example from southern Nepal.

    abstract:BACKGROUND:Immunization programs currently measure coverage by assessing the proportion of children 12-24 months who have been immunized but this does not address the important question of when the scheduled vaccines were administered. Data capturing the timing of vaccination in first 6 months, when severe disease is m...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2015.12.061

    authors: Hughes MM,Katz J,Englund JA,Khatry SK,Shrestha L,LeClerq SC,Steinhoff M,Tielsch JM

    更新日期:2016-02-10 00:00:00

  • Cross-reactive immune responses in mice after genetic vaccination with cDNA encoding hantavirus nucleocapsid proteins.

    abstract::Hantaviruses cause hemorrhagic fever with renal syndrome (HFRS) in about 150,000 individuals in Eurasia, and several hundred cases of hantavirus pulmonary syndrome (HPS) on the American continent annually. There is consequently a need for rapid diagnostics and effective prevention of hantaviral infections. In this stu...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.09.082

    authors: Lindkvist M,Lahti K,Lilliehöök B,Holmström A,Ahlm C,Bucht G

    更新日期:2007-02-19 00:00:00